Deutsch English Français

Contact

EP1663151

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...

News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...

Extract from the Register of European Patents

EP About this file: EP1663151

EP1663151 - MUCOACTIVE AGENTS FOR TREATING A PULMONARY DISEASE [Right-click to bookmark this link]
Status	The application has been refused Status updated on 11.04.2014 Database last updated on 02.11.2024
Most recent event Tooltip	11.04.2014	Refusal of application	published on 14.05.2014 [2014/20]
Applicant(s)	For all designated states Vectura Limited 1 Prospect West Chippenham, Wiltshire SN14 6FH / GB
	[2006/23]
Inventor(s)	01 / MORTON, David 1 Prospect West Chippenham Wiltshire SN14 6FH / GB
	02 / GANDERTON, David 1 Prospect West Chippenham Wiltshire SN14 6FH / GB
	03 / STANIFORTH, John 1 Prospect West Chippenham Wiltshire SN14 6FH / GB
	04 / KAMLAG, Yorick 1 Prospect West Chippenham Wiltshire SN14 6FH / GB
	[2006/23]
Representative(s)	Stephen, Robert John CMS Cameron McKenna Nabarro Olswang LLP Cannon Place 78 Cannon Street London EC4N 6AF / GB
	[N/P]
Former [2008/41]	Stephen, Robert John Olswang 90 High Holborn London WC1V 6XX / GB
Former [2006/23]	Gill, Siân Victoria, et al Venner Shipley LLP 20 Little Britain London EC1A 7DH / GB
Application number, filing date	04768478.2	15.09.2004
	[2006/23]
	WO2004GB03932
Priority number, date	GB20030021611	15.09.2003 Original published format: GB 0321611
	GB20030027723	28.11.2003 Original published format: GB 0327723
	[2006/23]
Filing language	EN
Procedural language	EN
Publication	Type:	A2 Application without search report
	No.:	WO2005025540
	Date:	24.03.2005
	Language:	EN
	[2005/12]
	Type:	A2 Application without search report
	No.:	EP1663151
	Date:	07.06.2006
	Language:	EN
	The application published by WIPO in one of the EPO official languages on 24.03.2005 takes the place of the publication of the European patent application.
	[2006/23]
Search report(s)	International search report - published on:	EP	16.06.2005
Classification	IPC:	A61K9/12, A61K9/14, A61K31/198, A61K31/727, A61P11/12	[2006/23]
	CPC:	A61K31/198 (EP,US); A61K47/36 (KR); A61K31/727 (EP,US); A61K9/0073 (EP,US); A61P11/00 (EP); A61P11/06 (EP); (+) A61P11/08 (EP); A61P11/10 (EP); A61P11/12 (EP); A61P29/00 (EP) (-)
Designated contracting states	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LI, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR [2006/23]
Extension states	AL	23.03.2006
	HR	23.03.2006
	LT	23.03.2006
	LV	23.03.2006
	MK	23.03.2006
Title	German:	MUKOAKTIVE MITTEL ZUR BEHANDLUNG EINER LUNGENERKRANKUNG	[2006/23]
	English:	MUCOACTIVE AGENTS FOR TREATING A PULMONARY DISEASE	[2006/23]
	French:	AGENTS MUCOACTIFS POUR LE TRAITEMENT D'UNE MALADIE PULMONAIRE	[2006/23]
Entry into regional phase	23.03.2006	National basic fee paid
	23.03.2006	Designation fee(s) paid
	23.03.2006	Examination fee paid
Examination procedure	23.03.2006	Examination requested [2006/23]
	31.05.2006	Amendment by applicant (claims and/or description)
	14.09.2007	Despatch of a communication from the examining division (Time limit: M06)
	25.03.2008	Reply to a communication from the examining division
	15.01.2009	Despatch of a communication from the examining division (Time limit: M04)
	15.05.2009	Reply to a communication from the examining division
	21.07.2010	Observations by third parties
	09.11.2011	Cancellation of oral proceeding that was planned for 25.11.2011
	25.11.2011	Date of oral proceedings (cancelled)
	28.11.2011	Despatch of a communication from the examining division (Time limit: M02)
	07.02.2012	Reply to a communication from the examining division
	12.03.2012	Observations by third parties
	10.04.2012	Despatch of a communication from the examining division (Time limit: M06)
	22.10.2012	Reply to a communication from the examining division
	04.01.2013	Observations by third parties
	30.10.2013	Observations by third parties
	18.11.2013	Application refused, date of legal effect [2014/20]
	18.11.2013	Date of oral proceedings
	18.12.2013	Despatch of communication that the application is refused, reason: substantive examination [2014/20]
	18.12.2013	Minutes of oral proceedings despatched
Divisional application(s)	EP10179071.5 / EP2277505
	The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 14.09.2007
Fees paid	Renewal fee
	11.09.2006	Renewal fee patent year 03
	12.09.2007	Renewal fee patent year 04
	31.03.2008	Renewal fee patent year 05
	28.09.2009	Renewal fee patent year 06
	29.09.2010	Renewal fee patent year 07
	29.09.2011	Renewal fee patent year 08
	27.09.2012	Renewal fee patent year 09
	27.09.2013	Renewal fee patent year 10
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited in	International search	[X]WO9402107 (KENNEDY THOMAS P [US]) [X] 1-8,15-29 * page 14; example 6 * * page 16, line 9 - line 12 *;
		[X]WO9804133 (CAVALIER PHARMACEUTICALS [US]) [X] 1-8,15-29 * the whole document * * page 14, line 1 - line 5 * * page 32; example 4 *;
		[X]WO9906025 (BAKER NORTON PHARMA [US]) [X] 1-9,15-40 * page 18, line 23 - page 19 * * page 21, line 20 - page 23, line 13 *;
		[XD]WO0115672 (UNIV ALBERTA [CA], et al) [XD] 1-29 * page 14; example 2 * * page 20; figure 5 * * figure 5 *;
		[X]WO03068188 (UNIV SOUTHAMPTON [GB], et al) [X] 1-9,13,15-29 * page 1, line 28 - page 2, line 16 * * page 5, line 29 - line 30 * * page 9, line 25 - line 31 * * page 15, line 14 - line 18 * * page 16, line 22 - line 25 * * page 24, line 26 - line 31 * * page 47, line 1 - line 13 * * page 52, line 15 - line 16 * * claim - *;
		[X]WO03068187 (UNIV SOUTHAMPTON [GB], et al) [X] 1-9,13,15-29 * page 17, line 18 - line 24 * * page 25, line 20 - page 26, line 2 * * page 30, line 8 - line 23 * * page 35, line 4 - line 16 *;
		[X]WO03068254 (UNIV SOUTHAMPTON [GB], et al) [X] 1-9,13,15-29 * page 3, line 29 - line 31 * * page 16, line 1 - line 12 * * page 51; example 5 *;
		[X] - LEE M M ET AL, "Effect of low molecular weight (MW) heparin on the elasticity of dog mucus", CLINICAL AND INVESTIGATIVE MEDICINE, & ANNUAL MEETING OF THE CANADIAN SOCIETY FOR CLINICAL INVESTIGATION, THE ROYAL COLLEGE OF PHYSICIANS A; TORONTO, ONTARIO, CANADA; SEPTEMBER 24-27, 1998, (1998), no. SUPPL., ISSN 0147-958X, page S102, XP009039322 [X] 1-9,15-29 * the whole document *
		[X] - LEE MM, H. GARRETT, E. SUDO, W. A. BOYD, AND M. KING, "Mucociliary clearance increase due to low molecular weight heparin", PEDIATR. PULMONOL, (1998), no. s17, page 386, XP000903996 [X] 1-9,15-29 * the whole document *
	Examination	WO0033811
		WO0061178
		WO0132144
		WO0200197
		US6475523
		WO03072080
		- TOMKIEWICZ ET AL, "A comparison of a new mucolytic N-acetylcysteine l-lysinate with N-acetylcysteine: Airway epithelial function and mucus changes in dog", PULMONARY PHARMACOLOGY, ACADEMIC PRESS LTD, GB LNKD- DOI:10.1006/PULP.1995.1035, (19951201), vol. 8, no. 6, ISSN 0952-0600, pages 259 - 265, XP005358878 DOI: http://dx.doi.org/10.1006/pulp.1995.1035
		- LUCAS PAUL ET AL, "Enhancement of small particle size dry powder aerosol formulations using an ultra low density additive", PHARMACEUTICAL RESEARCH (NEW YORK), (199910), vol. 16, no. 10, ISSN 0724-8741, pages 1643 - 1647
		- Jagdeep Shur ET AL, "Cospray-dried unfractionated heparin with L-leucine as a dry powder inhaler mucolytic for cystic fibrosis therapy", Journal of Pharmaceutical Sciences, (20081101), vol. 97, no. 11, doi:10.1002/jps.21362, ISSN 0022-3549, pages 4857 - 4868, XP055011201 DOI: http://dx.doi.org/10.1002/jps.21362
		- LI HAO-YING ET AL, "ENHANCED DISPERSIBILITY AND DEPOSITION OF SPRAY-DRIED POWDERS FOR PULMONARY GENE THERAPY", JOURNAL OF DRUG TARGETING, HARWOOD ACADEMIC PUBLISHERS GMBH, DE, (20030101), vol. 11, no. 7, doi:10.1080/10611860410001659786, ISSN 1061-186X, pages 425 - 432, XP009076596 DOI: http://dx.doi.org/10.1080/10611860410001659786
		- YAMASHITA C ET AL, "A NOVEL FORMULATION OF DRY POWDER FOR INHALATION OF PEPTIDES AND PROTEINS", RESPIRATORY DRUG DELIVERY, XX, XX, (19980101), pages 483 - 485, XP001023160
		- DENISOV S A ET AL, "ON THE POSSIBILITY OF LABORATORY REALIZATION OF AN UNSTEADY MHD-DYNAMO", DOKLADY PHYSICS, AMERICAN INSTITUTE OF PHYSICS, WOODBURY, US, (19990401), vol. 44, no. 4, ISSN 1028-3358, pages 231 - 233, XP000903996
		- H.-K. Chan, "Inhalation drug delivery devices and emerging technologies", Expert Opinion on Therapeutic Patents, (20030901), vol. 13, no. 9, doi:10.1517/eotp.13.9.1333.22942, ISSN 1354-3776, pages 1333 - 1343, XP055023307 DOI: http://dx.doi.org/10.1517/eotp.13.9.1333.22942
		- Nora Y.K. Chew ET AL, "Effect of amino acids on the dispersion of spray dried cromoglycate powders as aerosol", Respiratory Drug delivery, (20020101), vol. VIII, pages 743 - 746, XP055023304
		- TOMKIEWICZ R P ET AL, "MUCOLYTIC TREATMENT WITH N-ACETYLCYSTEINE L-LYSINATE METERED DOSE INHALER IN DOGS: AIRWAY EPITHELIAL FUNCTION CHANGES", EUROPEAN RESPIRATORY JOURNAL, MUNKSGAARD INTERNATIONAL PUBLISHERS, COPENHAGEN, DK, (19940101), vol. 7, no. 1, doi:10.1183/09031936.94.07010081, ISSN 0903-1936, pages 81 - 87, XP001063008 DOI: http://dx.doi.org/10.1183/09031936.94.07010081
		- LEDSON M ET AL, "Nebulized heparin in Burkholderia cepacia colonized adult cystic fibrosis patients", EUROPEAN RESPIRATORY JOURNAL, MUNKSGAARD INTERNATIONAL PUBLISHERS, COPENHAGEN, DK, (20010101), vol. 17, no. 1, ISSN 0903-1936, pages 36 - 38, XP002689425 DOI: http://dx.doi.org/10.1183/09031936.01.17100360
	by applicant	WO0243701
	other	WO0033811
		WO0061178
		WO0200197
		US6475523
		WO03068188
		WO03072080
		- LI H-Y. ET AL, "Enhanced dispersibility and deposition of spray-dried powders for pulmonary gene therapy.", JOURNAL OF DRUG TARGETING, (20030801), vol. 11, no. 7, pages 425 - 432, XP002413337 DOI: http://dx.doi.org/10.1080/10611860410001659786
		- CHEW N.Y.K. ET AL, "Effect of amino acids on the dispersion of spray dried cromoglycate powders as aerosol", RESPIRATORY DRUG DELIVERY, (20020101), vol. VIII, pages 743 - 746, XP055023304
		- LUCAS P. ET AL, "Enhancement of small particle size dry powder aerosol formulations using an ultra low density additive", PHARMACEUTICAL RESEARCH, (1999), vol. 16, no. 10, pages 1643 - 1647, XP002605016
		- LEDSON M. ET AL, "Nebulized heparin in Burkholderia cepacia colonized adult cystic fibrosis patients", EUR. RESPIR. J., (2001), vol. 17, pages 36 - 38, XP002689425 DOI: http://dx.doi.org/10.1183/09031936.01.17100360

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.2.25; 35p